---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-098783"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:07:57.699293+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics appoints Christopher Hite to Board of Directors

## Summary
- Christopher Hite appointed as Class III Director effective March 5, 2026.
- Initial option grant for 24,937 shares at $38.85, vesting monthly over three years.
- Annual cash retainer of $45,000, pro-rated for 2026.
- Eligible for annual option grants from 2027: lesser of 18,000 shares or up to $400k in grant date fair value.

## SEC filing metadata
- accession: 0001193125-26-098783
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312526098783/0001193125-26-098783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312526098783/vera-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-098783
- JSON: https://secwatch.observer/filing/0001193125-26-098783.json
- Plain text: https://secwatch.observer/filing/0001193125-26-098783.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.